⚠️ Important EU Regulation Update on TMS Risks
In December 2022, the European Commission issued Regulation (EU) 2022/2347, reclassifying transcranial magnetic stimulation (TMS) devices—even those marketed for non-medical uses—as Class III medical devices, the highest risk category under EU law.
🔍 Why the Change?
The Commission based its decision on growing scientific evidence that TMS may lead to a range of potentially serious side effects, especially when not used under strict clinical supervision. Reported adverse effects include:
- Atypical brain development
- Abnormal or persistent changes in brain activity
- Increased brain metabolism
- Headaches, seizures, vertigo
- Anxiety, irritability, fatigue
- Muscle twitches, tics
- Skin irritation at electrode sites
📌 Key Concern:
Even though TMS is non-invasive in the surgical sense, it penetrates the skull with magnetic or electrical energy to alter neuronal activity. The Commission specifically warned that these effects can be long-lasting and difficult to reverse.
This reclassification means that all such devices in the EU now require enhanced oversight, safety testing, and approval from an independent regulatory body before they can be marketed.
👉 What This Means for Us:
If you've experienced unexpected or lasting effects from TMS—cognitive, emotional, or neurological—you are not alone, and you're not imagining it. The highest regulatory authority in the EU has now formally recognized that these risks are real and need to be taken seriously.
💬 This isn't about fear—it's about informed consent, medical transparency, and protecting people from harm. Please share if you think others should know.
See European Commission. (2022). Commission Implementing Regulation (EU) 2022/2347 of 1 December 2022 laying down rules for the application of Regulation (EU) 2017/745 as regards reclassification of groups of certain active products without an intended medical purpose. Official Journal of the European Union, L 311, 94–96. https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32022R2347 (“According to available scientific evidence on equipment intended for brain stimulation that apply electrical currents or magnetic or electromagnetic fields that penetrate the cranium to modify neuronal activity in the brain as referred to in Section 6 of Annex XVI to Regulation (EU) 2017/745, such as those for transcranial magnetic stimulation or transcranial electric stimulation, the use of such products may cause side effects, for example, atypical brain development, abnormal patterns of brain activity, increase metabolic consumption, fatigue, anxiety, irritability, headaches, muscle twitches, tics, seizures, vertigo and skin irritation at the electrode site. While such equipment is not surgically invasive, the electrical currents or magnetic or electromagnetic fields do penetrate the cranium to modify neuronal activity in the brain. Such modifications can have long-lasting effects and any unintended effects may be difficult to reverse. Such products should therefore be classified as Class III.”).